A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease

Human Gene Therapy

Volumn 12, Issue 15, 2001, Pages 1907-1916

  Aitken, M L ^a   Moss, R B ^b   Waltz, D A ^c   Dovey, M E ^c   Tonelli, M R ^a   McNamara, S C ^a   Gibson, R L ^a   Ramsey, B W ^a   Carter, B J ^d   Reynolds, T C ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d Targeted Genetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DEOXYRIBONUCLEASE; MESSENGER RNA; RNA; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADULT; AEROSOL; ARTICLE; BRONCHOSCOPY; BRUSH BORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE TIME EFFECT RELATION; FEMALE; GENE TARGETING; GENE TRANSFER; HUMAN; LUNG; LUNG DISEASE; MALE; NEBULIZATION; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; SAFETY;

ADULT; ALLELES; CELLS, CULTURED; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOKINES; DEPENDOVIRUS; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG DISEASES; MALE; MUTATION; NEBULIZERS AND VAPORIZERS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 0034779927     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401753153956     Document Type: Article

References (47)

1. Episomal persistence of rep-deleted AAV-vectors in vitro and in vivo
2. In vivo model of adeno-associated virus vector persistence and rescue
3. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors
4. Effects of gamma irradation on the transduction of dividing cells and nondividing cells in brain and muscle of rats by adeno-associated virus vectors
5. A high-throughput hybridization method for titer determination of viruses and gene therapy vectors
6. Bronchoalveolar lavage: General approaches to correct for variability of dilution and lung permeability
7. Repeated delivery of adeno-associated virus vectors to the rabbit airway
8. Microbiology of sputum from patients at cystic fibrosis centers in the United States
9. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung
10. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer
11. Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia
12. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
13. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors
14. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis
15. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
16. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with adeno-associated virus vector
17. Expression of the cystic fibrosis conductance regulator from a novel adeno-associated virus promoter
18. A phase 1 study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease
19. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis
20. Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: Implications for gene therapy of cystic fibrosis
21. Transduction by adeno-associated virus vectors in the rabbit airway: Efficiency, persistence, and readministration
22. Successful readministration of AAV vectors to the mouse lung requires transient immunosuppression during the initial exposure
23. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis
24. Early pulmonary inflammation in infants with cystic fibrosis
25. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects
26. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis
27. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of AAV vectors
28. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation
29. Safety of aerosol administration of tgAAVCF vector for CF gene therapy in the non-human primate
30. Gene transfer and gene expression of tgAAVCF in nonhuman primates following repeated aerosolized administration
31. Use of adeno-associated virus as a general transduction vector for mammalian cells
32. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
33. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells
34. The diagnosis of cystic fibrosis: A consensus statement
35. DNA synthesis and topisomerase inhibitors increase transduction by adeno-associated virus vectors
36. Test methods used in the identification of commonly isolated aerobic gram negative bacteria
37. Production of beta-de-fensins by human airway epithelia
38. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
39. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions
40. Al-phaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection
41. Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells
42. Hydration kinetics of exocytosed mucins in cultured secretory cells of the rabbit trachea: A new model
43. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus
44. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus
45. Alveolar stem cell transduction by an adeno-associated virus vector